CHICAGO--(BUSINESS WIRE)--ElMindA, a company founded in Israel with a growing presence in the U.S., and the developer of Brain Network Activation (BNA™), was awarded today as one of the World Economic Forum’s “technology pioneers”, a selection of the world’s most innovative companies. BNA is a non-invasive technology that allows healthcare providers to accurately evaluate brain functions by mapping and monitoring changes in brain networks underlying such functions. This represents an important breakthrough for brain research and a potentially life-changing advance for the 2 billion people worldwide living with brain disorders. BNA provides physicians with tools to identify and evaluate the underlying brain activity responsible for disease or injury onset, progression and treatment efficacy and compare it to the brain activity of a healthy brain.
ElMindA was chosen by a professional jury among hundreds of candidates as one of the 49 selected companies. Thanks to its selection, it will have access to the most influential and sought-after business and political network in the world, and be invited to the World Economic Forum’s “Summer Davos” in Dalian, China, this September, or the Annual Meeting in Davos in January.
“We’re glad to see ElMindA make it to the selection,” says Fulvia Montresor, Head of Technology Pioneers at the World Economic Forum. “ElMindA is part of a group of entrepreneurs who are more aware of the crucial challenges of the world around them, and who are determined to do their part to solve those challenges with their company.”
As in previous years, American-based entrepreneurs continue to dominate the list of technology pioneers: they account for more than two-thirds of the recipients, followed by the United Kingdom (4), Israel and the Netherlands (2), and individual recipients of Canada, Germany, Ireland, Italy, Sweden and Taiwan, China. France and Spain were among the countries not counting a recipient.
“We are proud to be one of two Israel-based companies honored among the World Economic Forum’s technology pioneers,” said Ronen Gadot, CEO of ElMindA. “The human brain is extremely complicated, with about a hundred billion neurons and more than a hundred trillion connections. As we harness a greater understanding of the brain, BNA is revolutionizing our ability to assess and treat the brain across a broad range of previously elusive conditions such as brain injury, depression, pain, or memory loss.”
The Technology Pioneers were selected from among hundreds of applicants by a selection committee of 68 academics, entrepreneurs, venture capitalists and corporate executives. Notable members of the committee include Arianna Huffington (founder, Huffington Post) and Henry Blodget (editor-in-chief, Business Insider). The committee based its decisions on criteria including innovation, potential impact, working prototype, viability and leadership.
Past recipients include Google (2001), Wikimedia (2007), Mozilla (2007), Kickstarter (2011) and Dropbox (2011). More information on past winners can be found here.
For more information regarding this press release, please contact Peter Vanham, Media Lead, Technology Pioneers, at email@example.com, or +41 79 620 91 29.
The World Economic Forum is an international institution committed to improving the state of the world through public-private cooperation in the spirit of global citizenship. It engages with business, political, academic and other leaders of society to shape global, regional and industry agendas.
Incorporated as a not-for-profit foundation in 1971 and headquartered in Geneva, Switzerland, the Forum is independent, impartial and not tied to any interests. It cooperates closely with all leading international organizations (www.weforum.org).
About ElMindA Ltd. and BNA
Founded in 2006 to address an unmet need in the accurate, objective diagnosis and treatment of brain-related disorders, ElMindA is pioneering brain assessment technologies designed to inform critical decisions by providing a clear view of brain function over time. The company uses a data-driven approach to transform algorithmic science and neuroscience expertise into routine clinical practice, and is a preferred partner of industry-leading organizations based on the rigor of its science and technology development.
ElMindA has established a growing database of brain activity from both healthy subjects and patients with brain-related disorders. The database currently includes more than 10,000 BNA™ datasets, which provide a robust, clinically supported foundation to potentially help identify and manage neurological disorders such as ADHD or pain, and brain injuries such as concussion.
In 2014, BNA received U.S. Food and Drug Administration (FDA) clearance for use in 14- to 24- year-olds.
For more information, please visit www.elminda.com.